Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort.
Jansen van Vuuren J, Crocker-Buque T, Berry C, Viatushka D, Usmanova R, Nyang'wa BT, Parpieva N, Liverko I, Solodovnikova V, Sinha A. Jansen van Vuuren J, et al. Among authors: solodovnikova v. PLOS Glob Public Health. 2024 Sep 24;4(9):e0003057. doi: 10.1371/journal.pgph.0003057. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39316626 Free PMC article.
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang'wa B-T, Fielding KL, Berry C. Motta I, et al. Among authors: solodovnikova v. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0053624. doi: 10.1128/aac.00536-24. Epub 2024 Jun 6. Antimicrob Agents Chemother. 2024. PMID: 38842323 Free PMC article. Clinical Trial.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Among authors: solodovnikova v. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
Global Tuberculosis Network and TB/COVID-19 Global Study Group; Casco N, Jorge AL, Palmero DJ, Alffenaar JW, Fox GJ, Ezz W, Cho JG, Denholm J, Skrahina A, Solodovnikova V, Arbex MA, Alves T, Rabahi MF, Pereira GR, Sales R, Silva DR, Saffie MM, Salinas NE, Miranda RC, Cisterna C, Concha C, Fernandez I, Villalón C, Vera CG, Tapia PG, Cancino V, Carbonell M, Cruz A, Muñoz E, Muñoz C, Navarro I, Pizarro R, Cristina Sánchez GP, Vergara Riquelme MS, Vilca E, Soto A, Flores X, Garavagno A, Bahamondes MH, Merino LM, Pradenas AM, Revillot ME, Rodriguez P, Salinas AS, Taiba C, Valdés JF, Subiabre JN, Ortega C, Palma S, Castillo PP, Pinto M, Bidegain FR, Venegas M, Yucra E, Li Y, Cruz A, Guelvez B, Victoria Plaza R, Tello Hoyos KY, Cardoso-Landivar J, Van Den Boom M, Andréjak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Rivière F, Schlemmer F, Manika K, Diallo BD, Hassane-Harouna S, Artiles N, Mejia LA, Gupta N, Ish P, Mishra G, Patel JM, Singla R, Udwadia ZF, Alladio F, Angeli F, Calcagno A, Centis R, Codecasa LR, De Lauretis A, Esposito SMR, Formenti B, Gaviraghi A, Giacomet V, Goletti D, Gualano G, Matteelli A, Migliori GB, Motta I, Palmieri F, Pontali E, Prestileo T, Riccardi… See abstract for full author list ➔ Global Tuberculosis Network and TB/COVID-19 Global Study Group, et al. Among authors: solodovnikova v. Eur Respir J. 2023 Nov 29;62(5):2300925. doi: 10.1183/13993003.00925-2023. Print 2023 Nov. Eur Respir J. 2023. PMID: 37827576 Free PMC article.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. Among authors: solodovnikova v. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Safety of prolonged treatment with bedaquiline in programmatic conditions.
Zhurkin D, Gurbanova E, Campbell JR, Menzies D, Setkina S, Hurevich H, Solodovnikova V, Viatushka D, Altraja A, Skrahina A. Zhurkin D, et al. Among authors: solodovnikova v. ERJ Open Res. 2022 May 16;8(2):00685-2021. doi: 10.1183/23120541.00685-2021. eCollection 2022 Apr. ERJ Open Res. 2022. PMID: 35586446 Free PMC article.
Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.
Auchynka V, Kumar AMV, Hurevich H, Sereda Y, Solodovnikova V, Katovich D, Setkina S, Yedilbayev A, Skrahin A, Skrahina A. Auchynka V, et al. Among authors: solodovnikova v. Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1647. Monaldi Arch Chest Dis. 2021. PMID: 33470081 Free article.
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Solodovnikova V, Kumar AMV, Hurevich H, Sereda Y, Auchynka V, Katovich D, Klimuk D, Skrahin A, Setkina S, Charnysh I, Yedilbayev A, Skrahina A. Solodovnikova V, et al. Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1646. Monaldi Arch Chest Dis. 2021. PMID: 33470080 Free article.
TB and COVID-19 co-infection: rationale and aims of a global study.
Casco N, Jorge AL, Palmero D, Alffenaar JW, Fox G, Ezz W, Cho JG, Skrahina A, Solodovnikova V, Bachez P, Arbex MA, Galvão T, Rabahi M, Pereira GR, Sales R, Silva DR, Saffie MM, Miranda RC, Cancino V, Carbonell M, Cisterna C, Concha C, Cruz A, Salinas NE, Revillot ME, Farias J, Fernandez I, Flores X, Gallegos P, Garavagno A, Guajardo C, Bahamondes MH, Merino LM, Muñoz E, Muñoz C, Navarro I, Navarro J, Ortega C, Palma S, Pardenas AM, Pereira G, Castillo PP, Pinto M, Pizarro R, Rivas F, Rodriguez P, Sánchez C, Serrano A, Soto A, Taiba C, Venegas M, Vergara MS, Vilca E, Villalon C, Yucra E, Li Y, Cruz A, Guelvez B, Plaza R, Tello K, Andréjak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Rivière F, Schlemmer F, Gupta N, Ish P, Mishra G, Sharma S, Singla R, Udwadia ZF, Manika K, Diallo BD, Hassane-Harouna S, Artiles N, Mejia LA, Alladio F, Calcagno A, Centis R, Codecasa LR, D Ambrosio L, Formenti B, Gaviraghi A, Giacomet V, Goletti D, Gualano G, Kuksa L, Danila E, Diktanas S, Miliauskas S, Ridaura RL, López F, Torrico MM, Rendon A, Akkerman OW, Piubello A, Souleymane MB, Aizpurua E, Gonzales R, Jurado J, Loban A, Aguirre S, de Egea V, Irala S, Medina A, Sequera G, Sosa N, Váz… See abstract for full author list ➔ Casco N, et al. Among authors: solodovnikova v. Int J Tuberc Lung Dis. 2021 Jan 1;25(1):78-80. doi: 10.5588/ijtld.20.0786. Int J Tuberc Lung Dis. 2021. PMID: 33384052 No abstract available.
21 results